Find a Study

Change text size + -
 

CombiRX

Principal Investigator(s):Susan Scarberry M.D.
Sub Investigator(s):Rebecca Caillier M.D.
Condition:Multiple Sclerosis
Specialty:Neurology
Short Title:CombiRX
Sponsor:National Institutes of Health
Status:Open to enrollment
Description:A Multi-center, Doulbe-blind, Randomized Study comparing the combined use of Interferon beta-1a and Glatiramer Acetate to either agent alone in patients with Relapsing-Remitting Multiple Sclerosis
Purpose:To determine whether combined treatment with interferon beta-1a IM once weekly and glatiramer acetate SQ daily is more effective than either agent alone in treating relapsing-remitting multiple sclerosis as determined by reduction in relapse rate.
Phase:III
Key Inclusion Criteria:
Patients between 18 and 60 years of age diagnosed with relapsing-remitting multiple sclerosis with at least two exacerbations in the prior three years.
Key Exclusion Criteria:
Patients would be excluded with evidence of progressive MS, those who have prior use of any interferon beta or glatiramer acetate, chronic systemic steroid use, use of immunosuppressive or chemotherapeutic agents or IVIG, pregnancy or plans to become pregnant.
Contact:Tish Skarloken
Clinical Research Coordinator, Neurology
701-234-4091
tish.skarloken@meritcare.com
Last updated:Wednesday, July 27, 2005

 Return to Research Results

Research

For over two decades, MeritCare has been a leader in clinical research. Visit our online guide to learn more about our current research and clinical trials.

Quality

Every day, MeritCare is committed to quality health care and continuous improvements. Learn more in our online quality guide.